Among the published protocol and registries, 4 are measuring cancer markers, including cumulative double-strand deoxyribonucleic acid (dsDNA) damage of normal tissue and accumulated γH2ax foci, a marker of DNA damage56; change of proliferation genes and proteins, M30 antigen levels (a marker of residual tumor) and phosphorylated S660; changes in lymphocyte count61; and changes in prostate-specific antigen (PSA) kinetics and/or doubling time.62 The gene discussed is KLK3; the disease is neoplasm.